INVESTOR INSIGHTS ROUNDTABLES

For Investor Pass Holders Only. Closed-door conversations shaping the future of capital, strategy and global investment.

Step into invite-only roundtables where top investors trade sharp ideas, pressure-test big bets, and shape what comes next.

  • Date
    8 December 2026
  • Time
    10:30 am – 11:30 am
  • Location
    Investor Lounge
  • Access
    Investor Pass Holders Only
Fundraising

What LPs should actually look for in an emerging fund manager

Backing an emerging manager is a different underwriting problem than backing an established one — there's no ten-year track record to lean on, no fund III returns to point to, and the usual diligence checklist quietly stops working. Yet some of the strongest returns in venture come precisely from getting in early with the right GP before the market catches on. This is a practical session for LPs and allocators on how to evaluate conviction, discipline, and staying power in a manager who hasn't yet had the chance to prove it with numbers.

Audience

LPs

  • Olu Oyinsan
  • Managing Partner
  • Oui Capital
  • USA/Nigeria
Exits

Liquidity and Exits from Africa: Here’s Proof

A wave of early-stage exits and outsized returns — Moniepoint's rise to unicorn status, OmniRetail and LemFi delivering 5x and 29x for early backers, and other liquidity events now surfacing across fintech and adjacent sectors — signals that Africa's venture market has crossed into a new phase. This closed-door roundtable, hosted by a general partner who has lived this shift from the inside, moves the conversation from thesis to evidence: what these early exits actually reveal about the market's maturity, what separates the funds and founders who got there from those who didn't, and what it means for investors weighing first or expanded exposure to the region.

Audience

Non-Africa Investors

  • Margaret O'Connor
  • Chairperson
  • Launch Africa
  • Mauritius
AI

What agentic AI does to VC underwriting

Agentic AI is rewriting the rules of startup scaling, from lean teams and fast revenue to fragile moats, and with them the rules of VC underwriting. Topics include headcount-to-revenue benchmarks, defensibility when models commoditize, how to value AI-native margins and usage-based revenue, and what diligence should look like when the product itself can be rebuilt quickly.

Audience

All Investor Types

LIVX/Biotech
and Longevity

Underwriting AI-Driven Drug Discovery: How do you diligence a black box?

AI promises to make drug discovery faster and cheaper but how do investors know if it actually works before the results are in? Top investors debate where the real value is, and where the hype outruns the science.

Everyone says AI is transforming drug discovery. But how do you actually verify that from the outside, before the clinical data comes in? This roundtable brings together investors who've placed real bets in this space to talk candidly about what's working, what's overhyped, and how they make the call.

AI-native biotech companies claim their models compress discovery timelines and de-risk pipelines — but investors can't fully audit the model, can't easily verify claims years after the check is written.

Who's better positioned to win: AI-first biotechs, or incumbent pharma bolting AI onto existing discovery infrastructure and data?

Audience

AI, biotech, healthech Investors

Fundraising

How traditional Families Diversify and Partner on Deals

How to move beyond the core business, how to choose partners, and how to structure deals so that trust and returns both hold up.

How do families build conviction in unfamiliar sectors such as technology and life sciences without overpaying for the learning?

What makes a good co-investment partner: shared values, complementary expertise or aligned time horizons?

Audience

All Investor Types

  • Polina Alexandrova
  • Venture Partner
  • Infinitas Capital (LP)
  • Switzerland
Robotics

Physical AI's Capital Cycle: From Demo to Deployment

Robotics and physical AI just had their strongest quarter ever — over $16B raised across nearly 500 deals in Q1 2026 alone, after years of relatively muted funding. The real investor question isn't whether the space is hot, it's which of these companies are actually deploying (factory floors, logistics, defense) versus riding a wave of capital toward demos.

Audience

All Investor Types

  • Patt Pan
  • General Partner
  • Solaris Venture Partners
  • USA
Scale It

Bridging the Funding Gap: Unlocking Growth-Stage Capital in the UAE Investment Ecosystem

oes the availability of capital match the evolving needs of its companies? While early-stage and seed funding remain active, growth-stage businesses, particularly those seeking Series B and beyond, can face a more limited pool of investors and larger-scale capital. This roundtable will bring together investors, venture capital funds, family offices and institutional stakeholders to examine which sectors and stages remain underserved, where capital gaps are most pronounced, and how the UAE can attract more growth and late-stage investors. The discussion will explore opportunities to mobilise private and institutional capital, strengthen the funding pipeline, and ensure promising UAE-based companies can scale regionally and globally.

Audience

UAE Investors only

Managing Risk in a Vast and Mature Market: Staying Disciplined When Opportunity Is Everywhere

In large, mature markets, capital is abundant, competition is intense, and valuations can drift from fundamentals. The challenge is no longer finding deals but sizing, structuring, and sequencing them so that a portfolio holds up when conditions change. This roundtable brings together investors to share how they identify real risk beneath the surface, where they stay disciplined, and where they still lean in.

Audience

All Investor Types

  • Manoj Agarwal
  • Managing Partner
  • Seafund
  • India